Dunad Therapeutics has struck a new multi-million dollar deal with Novartis to develop nextgen protein degradation therapies.

Biopharmaceutical company Dunad Therapeutics (Dunad) has annouced that it has entered into a strategic collaboration with Novartis, to develop orally bioavailable covalent and protein degrading small molecule drugs.

Professor Patrick Gunning is the Co-founder, acting CEO and Chief Scientific Officer of Dunad Therapeutics and is thrilled to have entered this collaboration with Novartis.

Here are a few stories in all major biotech news outlets following the big announcement on November 2, 2021:

• Business Weekly: Dunad Therapeutics could earn $1.3bn add-ons from Novartis collaboration 
• BioCentury: BioCentury - Novartis gains access to Dunad’s non-E3 protein degrader platform
• Endpoints: Novartis enlists transatlantic startup to discover new protein degraders in $1.3B+ deal 

• Fierce Biotech: Novartis makes protein degrader play, inking deal with new British startup to access fruits of novel tech 

• PharmaPhorum: PharmaPhorum: UK biotech Dunad inks $1.3bn Novartis deal for its protein degraders 

• BioSpace: Novartis Links with UK's Dunad in $1.3 Billion Protein Degradation Deal 

• PharmaFocus/PharmaFile: Dunad Therapeutics and Novartis enter partnership to develop protein therapies 

• Evaluate Vantage: No giving up on degradation for Novartis